Navigation Links
Lilly Comments on 2011 Financial Guidance and Announces 2012 Financial Guidance
Date:1/5/2012

INDIANAPOLIS, Jan. 5, 2012 /PRNewswire/ --

  • Company expects to meet or exceed 2011 EPS guidance.
  • 2012 financial guidance reflects revenue and earnings declines due to Zyprexa patent expiration.
  • 2012 revenue anticipated to be between $21.8 billion and $22.8 billion.
  • Company expects to keep 2012 operating expenses essentially flat versus 2011.
  • 2012 earnings per share forecasted to be in the range of $3.10 - $3.20.
  • R&D pipeline includes 12 molecules in Phase III development at end of 2011, exceeding goal of 10.
  • Mid-term guidance through 2014 reconfirmed with minimum annual results of at least $20 billion in revenue, $3 billion in net income and $4 billion in operating cash flow.
  • Company reaffirms commitment to fund dividend at least at current level.

Eli Lilly and Company (NYSE: LLY) today commented on its 2011 financial guidance and announced its financial guidance for 2012. The company also reconfirmed its mid-term guidance through 2014.

For 2011, the company expects to meet or exceed its current earnings per share guidance. 2011 EPS guidance is currently in the range of $3.84 to $3.89 on a reported basis, or $4.30 to $4.35 on a non-GAAP basis when excluding $.23 of in-process research and development charges associated with the Boehringer Ingelheim collaboration and $.18 of asset impairment and restructuring charges through the first nine months of 2011, as well as an estimated $.05 asset impairment charge in the fourth quarter of 2011 related to the Xigris® withdrawal. For 2012, the company expects earnings per share to be in the range of $3.10 to $3.20 on both a reported and non-GAAP basis.

"2012 is an important year for Lilly, having entered the period when we face patent expirat
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
3. Lilly and Glenmark Pharmaceuticals Announce License Agreement
4. Lilly Receives NCQA Design Certification for Depression Care Management Program
5. JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers
6. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
7. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
8. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
9. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
10. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
11. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... NEW YORK and LONDON ... in global orthopedic industry are expected to grow at ... consumption in terms of value and volume. Hip, knee ... the developed world while in emerging economies they have ... failure rates are challenging the use of composites. Non-metallic ...
(Date:12/24/2014)... DIEGO , Dec. 23, 2014 ResMed (NYSE: ... significant patent infringement action against Chinese medical device manufacturer BMC ... (ITC) ruled today that BMC,s masks listed below infringe ResMed,s ... or selling these masks in the United States ... iVolve N2 nasal mask , Willow nasal pillows mask ...
(Date:12/24/2014)... , Dec. 23, 2014  Lockton Dunning Benefits, ... Lockton Companies, announced the addition of Vice President ... join Lockton Dunning,s Pharmacy Consulting team, Excelsior Solutions. ... relevant industry experience to the position.  Most recently, ... Sales at Diplomat Specialty Pharmacy, where she has ...
Breaking Medicine Technology:Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 3ResMed Wins Patent Infringement Lawsuit Against Chinese Manufacturer BMC Medical 2Kim Foerster Joins Lockton Companies 2
... Calif., May 18, 2011 Bayer HealthCare Pharmaceuticals, ... ONXX ) today announced results from a Phase ... with locally advanced or metastatic breast cancer previously ... Nexavar was associated with statistically significant improvements in ...
... SEATTLE, May 18, 2011 Dendreon Corporation (Nasdaq: ... poster presentation detailing clinical trial plans for PROVENGE® (sipuleucel-T) and ... upcoming American Society for Clinical Oncology annual meeting in Chicago, ... on Monday, June 6, 2011, from 8:00 a.m. to 12:00 ...
Cached Medicine Technology:Nexavar in Combination with Chemotherapy Improves Progression-Free Survival in Patients with Advanced Breast Cancer in Phase 2 Study 2Nexavar in Combination with Chemotherapy Improves Progression-Free Survival in Patients with Advanced Breast Cancer in Phase 2 Study 3Nexavar in Combination with Chemotherapy Improves Progression-Free Survival in Patients with Advanced Breast Cancer in Phase 2 Study 4Nexavar in Combination with Chemotherapy Improves Progression-Free Survival in Patients with Advanced Breast Cancer in Phase 2 Study 5Nexavar in Combination with Chemotherapy Improves Progression-Free Survival in Patients with Advanced Breast Cancer in Phase 2 Study 6Nexavar in Combination with Chemotherapy Improves Progression-Free Survival in Patients with Advanced Breast Cancer in Phase 2 Study 7Nexavar in Combination with Chemotherapy Improves Progression-Free Survival in Patients with Advanced Breast Cancer in Phase 2 Study 8Dendreon Announces Clinical Trial Plans for PROVENGE and DN24-02 at the American Society of Clinical Oncology Annual Meeting 2Dendreon Announces Clinical Trial Plans for PROVENGE and DN24-02 at the American Society of Clinical Oncology Annual Meeting 3Dendreon Announces Clinical Trial Plans for PROVENGE and DN24-02 at the American Society of Clinical Oncology Annual Meeting 4
(Date:12/26/2014)... 2014 Parker & Sons, Inc. ... in heating, cooling and plumbing contractor services throughout ... services in 2014 with regard to air-conditioning systems. ... is known for its incredibly hot summers. Working ... intricacies and details of a wide variety of ...
(Date:12/25/2014)... 2014 The click strand ... strength and durability. Today, the business announces a ... valid until Jan. 30, 2015. , Click strand ... hardwood. BambooFlooringChina.com is a well-known brand in the ... to find a reliable bamboo flooring supplier. , ...
(Date:12/25/2014)... 2014 Product liability lawsuits filed in ... ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward in federal ... issued in the U.S. District Court, Northern District of ... open conference on January 7, 2015, at the Paul ... West Palm Beach, Florida. The Conference is scheduled to ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying ... of discounted prom dresses, most of which are priced ... the company, the promotion is valid until Jan. 22, ... the UK market. , The prom dresses in this ... styles: A-line strapless, empire strapless chiffon, one shoulder, floor-length, ...
(Date:12/25/2014)... sells many bamboo products and the business is famous ... announces big discounts on its bamboo mats , which ... the world’s leader in bamboo flooring. According to the ... 2015. , The bamboo mats are made from well-treated ... the bamboo strips for the mats are boiled and ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2
... the US consumer product safety commission. This number is far ... are mainly related to the children as they are the ... in an increase in the emergency room visit. ... the sidewalk, through crowded malls and playgrounds. , ...
... cause of concern as most of them are related to ... health problems due to which people abstained from work. ... and Development (CIPD) on about 30,000 workers revealed that mental ... to muscle related problems like bad back. ,The ...
... of Alzheimer's disease nationwide, both the New York State ... a resolution aimed at raising awareness of the importance ... brain disorder. ,The resolution declared November 2007 ... as Memory Screening Day in New York State. ...
... Advanced Bio-Surfaces, Inc., (ABS) an orthopedic implant developer and ... been completed in the United States using the OrthoGlide ... implant designed to relieve chronic, disabling pain, due to ... ,"There has been a significant increase in ...
... products and medicines has the potential to reach Rs.120 billion ... of exclusive export promotion zones (EPZ) across India, says ... accelerated with the setting up of EPZs in about 12 ... over 25 percent in countries like the US, Britain, Spain, ...
... also known as marijuana or ganja, can help in ... occur when body tissues are attacked by its own ... at the University of Bonn, used tetrahydrocannabinol (THC), the ... and found that it reduced skin allergies. ...
Cached Medicine News:Health News:1,600 Roller Shoe Injuries Reported 2Health News:Mental Illness Foremost Reason for Absenteeism 2Health News:New York Legislature Highlights for Awareness of Alzheimer's Disease 2Health News:New York Legislature Highlights for Awareness of Alzheimer's Disease 3Health News:Export of Herbal Products to Reach Rs.120 Billion by 2012: Study 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: